Capricor stock jumps after FDA provides path forward for DMD therapy
PositiveFinancial Markets

Capricor's stock has surged following the FDA's announcement of a clear path forward for its therapy targeting Duchenne muscular dystrophy (DMD). This development is significant as it not only boosts investor confidence but also brings hope to families affected by DMD, a severe genetic disorder. The FDA's support could accelerate the therapy's availability, potentially transforming the lives of many patients.
— Curated by the World Pulse Now AI Editorial System